Chronic Myeloid Leukemia Medical Services in China

Chronic Myeloid Leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the uncontrolled proliferation of myeloid lineage cells—particularly granulocytes—in the bone marrow and peripheral blood. It is defined molecularly by the presence of the Philadelphia chromosome (Ph+), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)], which generates the BCR-ABL1 fusion oncogene. This chimeric gene encodes a constitutively active tyrosine kinase that drives aberrant cell survival, proliferation, and impaired apoptosis—fundamental hallmarks of CML pathogenesis. CML typically progresses through three clinical phases: chronic phase (CP), accelerated phase (AP), and blast phase (BP); most patients are diagnosed in CP, where symptoms are often subtle or absent. Epidemiologically, CML accounts for approximately 15% of adult leukemias in Western populations, with an annual incidence of 1–2 cases per 100,000 individuals. It predominantly affects adults, with a median age at diagnosis of 64 years; pediatric cases are rare (<5% of all CML). No strong environmental or lifestyle risk factors have been consistently identified—unlike many cancers, CML is not linked to smoking, diet, or occupational exposures. Ionizing radiation remains the only well-established risk factor, notably observed in atomic bomb survivors. The disease’s chronic nature and lifelong treatment requirements significantly impact quality of life: patients may experience persistent fatigue, early satiety (due to splenomegaly), night sweats, weight loss, and anxiety related to treatment adherence, monitoring burden (e.g., monthly PCR testing), and fear of progression or resistance. While modern tyrosine kinase inhibitors (TKIs)—such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib—have transformed CML into a manageable chronic condition with near-normal life expectancy for most CP patients, long-term toxicities (e.g., cardiovascular events, pleural effusions, metabolic disturbances) and financial strain from prolonged therapy remain critical concerns. Psychosocial support, patient education, and integrated care models are increasingly emphasized to preserve functional status and emotional well-being throughout decades of treatment.

Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative neoplasm driven by the BCR-ABL1 fusion oncogene, resulting from the reciprocal translocation t(9;22)(q34;q11.2)—the Philadelphia chromosome. Diagnosis requires confirmation of BCR-ABL1 via quantitative reverse transcription polymerase chain reaction (qRT-PCR), fluorescence in situ hybridization (FISH), or cytogenetic analysis. Treatment strategy is risk-stratified and response-guided, with the primary goal of achieving deep molecular responses to prevent progression to accelerated or blast phase disease.

Conservative management plays a supportive role rather than serving as definitive therapy. It includes regular hematologic monitoring (complete blood count every 2–4 weeks during initial therapy), assessment of spleen size, and evaluation for symptoms such as fatigue, night sweats, weight loss, or early satiety. Patients with low-risk CML (Sokal or EUTOS score low) and minimal symptom burden may undergo observation only during the very early chronic phase—though this is exceedingly rare in contemporary practice due to the high efficacy and tolerability of tyrosine kinase inhibitors (TKIs). Conservative measures also encompass transfusion support for symptomatic anemia or thrombocytopenia, hydroxyurea for rapid leukocyte reduction prior to TKI initiation, and allopurinol or rasburicase for tumor lysis prophylaxis in high-burden cases. Infection surveillance and vaccination (e.g., pneumococcal, influenza, and SARS-CoV-2 vaccines) are integral, particularly given the immunomodulatory effects of long-term TKI therapy.

Medication remains the cornerstone of CML treatment. First-line therapy consists of second-generation TKIs—nilotinib, dasatinib, or bosutinib—or imatinib, though the latter is now less favored due to inferior depth and speed of molecular response. Second-generation agents achieve major molecular response (MMR; BCR-ABL1 ≤0.1% IS) in >70% of patients at 12 months versus ~60% with imatinib. Third-generation TKI ponatinib is reserved for patients with T315I mutation or those failing ≥2 prior TKIs. Asciminib, a first-in-class STAMP inhibitor (specifically targeting the ABL myristoyl pocket), has demonstrated robust efficacy and improved safety in refractory/intolerant CML, including T315I-mutated disease. Treatment response is monitored rigorously: cytogenetics at 3 and 6 months; qRT-PCR every 3 months for the first 2 years, then every 3–6 months upon sustained MMR. Failure or suboptimal response triggers mutation analysis (ABL1 kinase domain sequencing) and therapeutic adjustment. Treatment-free remission (TFR) is a realistic goal for eligible patients—those maintaining deep molecular response (MR4.5; BCR-ABL1 ≤0.0032% IS) for ≥2 years—under close molecular surveillance after TKI discontinuation.

Surgical treatment has no curative role in CML. Splenectomy may be considered in rare instances of massive, symptomatic splenomegaly unresponsive to medical therapy or causing mechanical complications (e.g., gastric compression, infarction, or hypersplenism with severe cytopenias). However, it carries significant morbidity—including infection risk (especially encapsulated organisms), thromboembolism, and potential acceleration of extramedullary disease—and is largely obsolete in the TKI era. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative modality but is restricted to patients with TKI resistance, intolerance, disease progression to accelerated/blast phase, or specific high-risk features (e.g., additional chromosomal abnormalities in Ph+ cells). Due to substantial transplant-related mortality (15–25%) and morbidity (graft-versus-host disease, infections), allo-HSCT is not recommended in chronic-phase CML with adequate TKI response. Its use has declined markedly since the advent of potent TKIs, now representing <5% of all CML treatments in high-resource settings.

China offers distinct advantages in CML care. First, national health insurance coverage includes multiple TKIs—including imatinib, nilotinib, dasatinib, and increasingly asciminib—with significantly reduced out-of-pocket costs following inclusion in the National Reimbursement Drug List (NRDL). Second, China’s centralized, high-volume leukemia centers (e.g., Peking University People’s Hospital, Ruijin Hospital, Sun Yat-sen University Cancer Center) maintain standardized, protocol-driven monitoring aligned with ELN and NCCN guidelines, supported by robust real-time qRT-PCR infrastructure and centralized reference laboratories. Third, China leads globally in TKI pharmacovigilance and real-world evidence generation through large-scale registries like the Chinese CML Registry, enabling rapid identification of regional toxicity patterns (e.g., higher incidence of pleural effusion with dasatinib in East Asian populations) and informing personalized dosing strategies. Fourth, domestic innovation has accelerated: Hefei-based biotech firms have developed novel TKIs (e.g., olverembatinib) approved in China for T315I-mutated CML, offering alternatives where ponatinib access is limited. Finally, integrated traditional Chinese medicine (TCM) adjuncts—such as Jiedu Xiaozheng decoction—are used under rigorous clinical protocols to mitigate TKI-induced adverse effects (e.g., hepatotoxicity, myelosuppression), with emerging randomized data supporting improved quality-of-life metrics without compromising molecular response.

Recovery and long-term management emphasize adherence, surveillance, and lifestyle optimization. Patients must maintain strict TKI adherence (>90% dose intensity); missed doses correlate strongly with resistance development. Annual cardiovascular risk assessment (lipid panel, echocardiogram if on dasatinib, ECG for QTc prolongation with nilotinib) is mandatory. Bone mineral density screening is recommended after 5 years of TKI therapy due to increased osteoporosis risk. Psychosocial support—including counseling and peer-led survivorship programs—is vital, as anxiety about relapse and financial toxicity persist despite treatment advances. Nutrition should prioritize anti-inflammatory foods (leafy greens, fatty fish, berries) and avoid grapefruit (CYP3A4 inhibition) with most TKIs. Moderate aerobic exercise (150 min/week) improves fatigue and immune resilience. Pregnancy planning requires multidisciplinary coordination: TKI cessation or switch to safer agents (e.g., imatinib) preconception, with close fetal monitoring. Finally, patients should receive annual influenza and pneumococcal vaccines, avoid live vaccines during active TKI therapy, and seek prompt evaluation for persistent fever, bruising, or lymphadenopathy—potential signs of progression. With modern TKI regimens, median overall survival exceeds 20 years, and many patients attain near-normal life expectancy when managed in specialized hematology centers.